Evaluating Nanomedicines: Obstacles and Advancements
Continued advancements in nanotechnology are expanding the boundaries of medical research, most notably as drug delivery agents for treatment against cancer. Drug delivery with nanotechnology can offer greater control over the biodistribution of therapeutic agents to improve the therapeutic index. In the last 20 years, a number of nanomedicines have transitioned into the clinic. As nanomedicines evolve, techniques to properly evaluate their safety and efficacy must also evolve. Characterization methods for nano-based materials must be adapted to the demands of nanomedicine developers and regulators. This second edition book provides updated characterization protocols designed to address the clinical potential of nanomedicines during their preclinical development. In this chapter, the characterization challenges of nanoparticles intended for drug delivery will be discussed, along with examples of advancements and improvements in nanomedicine characterization.
Key wordsNanoparticles Nanomedicine Therapy Efficacy Toxicity Active targeting Passive targeting
This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.
- 4.Boswell GW, Buell D, Bekersky I (1998) AmBisome (Liposomal Amphotericin B): a comparative review. J Clin Pharmacol 38(7):583–592. https://doi.org/10.1002/j.1552-4604.1998.tb04464.x CrossRefPubMedGoogle Scholar
- 11.(2016) Celator Pharmaceuticals® presented phase 3 trial results in patients with high-risk acute myeloid leukemia demonstrating VYXEOS™ (CPX-351) significantly improved overall survival. Ewing, NJ. http://www.prnewswire.com/news-releases/celator-announces-phase-3-trial-for-vyxeos-cpx-351-in-patients-with-high-risk-acute-myeloid-leukemia-demonstrates-statistically-significant-improvement-in-overall-survival-300235620.html
- 12.Prabhakar U, Maeda H, Jain RK, Sevick-Muraca EM, Zamboni W, Farokhzad OC, Barry ST, Gabizon A, Grodzinski P, Blakey DC (2013) Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 73(8):2412–2417. https://doi.org/10.1158/0008-5472.can-12-4561 CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Hrkach J, Von Hoff D, Mukkaram Ali M, Andrianova E, Auer J, Campbell T, De Witt D, Figa M, Figueiredo M, Horhota A, Low S, McDonnell K, Peeke E, Retnarajan B, Sabnis A, Schnipper E, Song JJ, Song YH, Summa J, Tompsett D, Troiano G, Van Geen HT, Wright J, LoRusso P, Kantoff PW, Bander NH, Sweeney C, Farokhzad OC, Langer R, Zale S (2012) Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med 4(128):128ra139. https://doi.org/10.1126/scitranslmed.3003651 CrossRefGoogle Scholar
- 16.Kamoun WS, Luus L, Pien C, Kornaga T, Oyama S, Huang ZR, Tipparaju S, Kirpotin DB, Marks JD, Koshkaryev A, Geddie M, Xu L, Lugovosky A, Drummond DC (2016) Abstract 871: nanoliposomal targeting of ephrin receptor A2 (EphA2): preclinical in vitro and in vivo rationale. Cancer Res 76(14 Supplement):871–871. https://doi.org/10.1158/1538-7445.am2016-871 CrossRefGoogle Scholar
- 17.Kirpotin DB, Tipparaju S, Huang ZR, Kamoun WS, Pien C, Kornaga T, Oyama S, Olivier K, Marks JD, Koshkaryev A, Schihl SS, Fetterly G, Schoeberl B, Noble C, Hayes M, Drummond DC (2016) Abstract 3912: MM-310, a novel EphA2-targeted docetaxel nanoliposome. Cancer Res 76(14 Supplement):3912–3912. https://doi.org/10.1158/1538-7445.am2016-3912 CrossRefGoogle Scholar
- 21.Bao G, Mitragotri S, Tong S (2013) Multifunctional nanoparticles for drug delivery and molecular imaging. Annu Rev Biomed Eng 15(1):253–282. https://doi.org/10.1146/annurev-bioeng-071812-152409 CrossRefPubMedGoogle Scholar
- 23.van Elk M, Murphy BP, Eufrásio-da-Silva T, O’Reilly DP, Vermonden T, Hennink WE, Duffy GP, Ruiz-Hernández E (2016) Nanomedicines for advanced cancer treatments: transitioning towards responsive systems. Int J Pharm 515(1–2):132–164. https://doi.org/10.1016/j.ijpharm.2016.10.013 CrossRefPubMedGoogle Scholar
- 25.Landon CD, Park JY, Needham D, Dewhirst MW (2011) Nanoscale drug delivery and hyperthermia: the materials design and preclinical and clinical testing of low temperature-sensitive liposomes used in combination with mild hyperthermia in the treatment of local cancer. Open Nanomed J 3:38–64. https://doi.org/10.2174/1875933501103010038 CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Crist RM, Grossman JH, Patri AK, Stern ST, Dobrovolskaia MA, Adiseshaiah PP, Clogston JD, McNeil SE (2013) Common pitfalls in nanotechnology: lessons learned from NCI’s nanotechnology characterization laboratory. Integr Biol (Camb) 5(1):66–73. https://doi.org/10.1039/c2ib20117h CrossRefGoogle Scholar
- 33.Wilke RA, Lin DW, Roden DM, Watkins PB, Flockhart D, Zineh I, Giacomini KM, Krauss RM (2007) Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 6(11):904–916. https://doi.org/10.1038/nrd2423 CrossRefPubMedPubMedCentralGoogle Scholar